These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14654716)

  • 1. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors.
    Molina R; Filella X; Augé JM; Fuentes R; Bover I; Rifa J; Moreno V; Canals E; Viñolas N; Marquez A; Barreiro E; Borras J; Viladiu P
    Tumour Biol; 2003; 24(4):209-18. PubMed ID: 14654716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer.
    Fu Y; Li D; Zhu Y; Yan S; Wang X; Lian Z; Xie Q; He Z
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
    Trulson I; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
    Sun A
    Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
    Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
    Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers.
    Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
    Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between HRCT signs and levels of CA125, SCCA, and NSE for different pathological types of lung cancer.
    Wu LH; Chen L; Wang QY; Wang YT
    Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4162-4168. PubMed ID: 37203842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights on Old Biomarkers Involved in Tumor Microenvironment Changes and Their Diagnostic Relevance in Non-Small Cell Lung Carcinoma.
    Wadowska K; Błasiak P; Rzechonek A; Bil-Lula I; Śliwińska-Mossoń M
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating lung cancer biomarkers: From translational research to clinical practice.
    Qian X; Meng QH
    Tumour Biol; 2024; 46(s1):S27-S33. PubMed ID: 37927289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer.
    Li Y; Xuan J; Song Y; Qi W; He B; Wang P; Qin L
    ACS Nano; 2016 Jan; 10(1):1640-7. PubMed ID: 26690745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HSP90
    Zhou W; Yang Y; Wang Z; Liu Y; Lari Najafi M
    J Healthc Eng; 2021; 2021():6929971. PubMed ID: 34721827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of Reference Intervals of Cytokeratin 19 Fragment Antigen 21-1 in Korean Adults.
    Yoon S; Lim YK; Kim HR; Lee MK; Kweon OJ
    Ann Lab Med; 2023 Jan; 43(1):82-85. PubMed ID: 36045060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis.
    Mohamed E; García Martínez DJ; Hosseini MS; Yoong SQ; Fletcher D; Hart S; Guinn BA
    Carcinogenesis; 2024 Feb; 45(1-2):1-22. PubMed ID: 38066655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.
    van Delft FA; Schuurbiers MMF; Muller M; Burgers SA; van Rossum HH; IJzerman MJ; van den Heuvel MM; Koffijberg H
    Tumour Biol; 2024; 46(s1):S269-S281. PubMed ID: 37545289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Iodine 125 Seeds (I-125) Responding to Lung Squamous Cell Carcinoma.
    Ni Q; Pan C; Guo Q; Wang P; Yang Y; Zhang W; Dai S
    Dose Response; 2022; 20(2):15593258221103373. PubMed ID: 35615569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: Impact of HSP90
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9796148. PubMed ID: 37860380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
    Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
    Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.